Brief: Nurexone Announces Promising Preclinical Results In Restoring Vision After Optic Nerve Damage
06/12/2024 21:35
Dec 6 (Reuters) - Nurexone Biologic Inc NRX.V :
* NUREXONE ANNOUNCES PROMISING PRECLINICAL RESULTS IN
RESTORING
VISION AFTER OPTIC NERVE DAMAGE
* NUREXONE BIOLOGIC INC - EXPANDED ANALYSES OF STUDY DATA
SHOWED
RECOVERY OF SIGNAL TRANSMISSION IN TREATED EYES COMPARED TO
UNTREATED CONTROLS
* NUREXONE BIOLOGIC INC - ANNOUNCED FINDINGS FROM EXPANDED
PRECLINICAL STUDY OF POTENTIAL OF EXOPTEN, FOR REPAIRING OPTIC
NERVE DAMAGE
Source text: ID:nGNX3PgbNB
Further company coverage: NRX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement